Glycogen synthase kinase 3 involvement in the excessive proinflammatory response to LPS in patients with decompensated cirrhosis

J Hepatol. 2011 Oct;55(4):784-93. doi: 10.1016/j.jhep.2010.12.039. Epub 2011 Feb 18.

Abstract

Background & aims: In decompensated cirrhosis, the early innate immune response to the Toll-like receptor 4 (TLR4) agonist, lipopolysaccharides (LPS), is characterized by a hyper-production of pro-inflammatory cytokines and hypo-production of the anti-inflammatory cytokine IL-10. In LPS-stimulated non-cirrhotic immune cells, the constitutively active glycogen synthase kinase (GSK) 3 favors pro- vs. anti-inflammatory cytokines, by acting on gene induction. However, in these cells, TLR4 dampens its own pro-inflammatory response by inducing early (within minutes) AKT-mediated phosphorylation of GSK3β (one of two GSK3 isoforms) on Ser9. Phosphorylation of GSK3β (Ser9) inhibits its activity, decreases pro-inflammatory cytokines, and increases IL-10. Thus, we investigated the role of GSK3 in LPS-induced cytokine production by peripheral blood mononuclear cells (PBMCs) or monocytes from patients with advanced cirrhosis and normal subjects.

Methods: Cells were pre-incubated with or without GSK3 inhibitor (SB216763 or lithium chloride) for 1h and then stimulated with LPS. Cytokine production was assessed at mRNA and secreted proteins levels, by real-time RT-PCR at 1h and ELISA at 20 h, respectively. GSK3β phosphorylation was assessed using Western blotting.

Results: In cirrhotic and normal PBMCs pretreated with GSK3 inhibitors, LPS-induced production of pro-inflammatory proteins TNF-α and IL-12p40 was significantly decreased while that of IL-10 was increased. LPS-induced, AKT-mediated phosphorylation of GSK3β on Ser9 found in normal monocytes, was abolished in cirrhotic cells.

Conclusions: GSK3 is involved in the early TLR4-mediated pro-inflammatory response in patients with decompensated cirrhosis. This was associated with a defect in AKT-mediated GSK3β phosphorylation resulting in unrestricted 'pro-inflammatory' activity of the enzyme.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Adult
  • Aged
  • Cells, Cultured
  • Female
  • Gene Expression Regulation, Enzymologic / immunology
  • Glycogen Synthase Kinase 3 / antagonists & inhibitors
  • Glycogen Synthase Kinase 3 / genetics
  • Glycogen Synthase Kinase 3 / immunology*
  • Glycogen Synthase Kinase 3 / metabolism*
  • Glycogen Synthase Kinase 3 beta
  • Hepatitis / immunology*
  • Hepatitis / metabolism
  • Humans
  • Indoles / pharmacology
  • Interleukin-10 / immunology
  • Interleukin-10 / metabolism
  • Interleukin-12 / immunology
  • Interleukin-12 / metabolism
  • Lipopolysaccharides / pharmacology
  • Lithium Chloride / pharmacology
  • Liver Cirrhosis / immunology*
  • Liver Cirrhosis / metabolism
  • Male
  • Maleimides / pharmacology
  • Middle Aged
  • Monocytes / immunology
  • Monocytes / metabolism
  • Proto-Oncogene Proteins c-akt / genetics
  • Severity of Illness Index
  • Signal Transduction / immunology*
  • Toll-Like Receptor 4 / immunology
  • Toll-Like Receptor 4 / metabolism

Substances

  • Adjuvants, Immunologic
  • IL10 protein, human
  • Indoles
  • Lipopolysaccharides
  • Maleimides
  • SB 216763
  • TLR4 protein, human
  • Toll-Like Receptor 4
  • Interleukin-10
  • Interleukin-12
  • AKT1 protein, human
  • AKT2 protein, human
  • AKT3 protein, human
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt
  • Glycogen Synthase Kinase 3
  • glycogen synthase kinase 3 alpha
  • Lithium Chloride